Charles M. Lillis - Sep 1, 2021 Form 3 Insider Report for SomaLogic, Inc. (SLGC)

Role
Director
Signature
/s/ Ruben Gutierrez, Attorney-in-Fact
Stock symbol
SLGC
Transactions as of
Sep 1, 2021
Transactions value $
$0
Form type
3
Date filed
9/10/2021, 07:04 PM
Next filing
Dec 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLGC Class A Common Stock, par value $0.0001 277K Sep 1, 2021 Direct F1
holding SLGC Class A Common Stock, par value $0.0001 101K Sep 1, 2021 See Footnote F1, F2
holding SLGC Class A Common Stock, par value $0.0001 12.6K Sep 1, 2021 See Footnote F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLGC Employee Stock Option (Right to Buy) Sep 1, 2021 Class A Common Stock, par value $0.0001 21K $4.77 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock.
F2 Reflects stock held of record by The Lillis Foundation. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares.
F3 Reflects stock held of record by CAG LLC. Mr. Lillis may be deemed to be a beneficial owner of the shares held directly by The Lillis Foundation as a result of Mr. Lillis' voting and dispositive power with respect to the shares.
F4 The shares underlying the option vest in 12 equal monthly installments starting on the 1st of the first full month following the date of the grant.
F5 In connection with the Closing, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards.